Kun Run Biotech Raises $8 Million from OrbiMed

Kun Run Biotechnology, a biopharma focused on peptide and small molecule drugs, has raised $8 million in a private placement with Caduceus Asia Partners, LP, a fund managed by OrbiMed Advisors, and Mr. Xueyun Cui, who is both Chairman and majority stockholder of Kun Run. In a statement, Mr. Cui said that OrbiMed’s participation would give Kun Run a leg up in its plan to sell products globally. More details... Stock Symbol: (OTCBB: KURU)